《新股消息》新纽科技(09600.HK)公开发售超购逾445倍上限定价 一手中签率16%
IT解决方案提供商新纽科技(09600.HK)公布招股结果,发售价定於4.36元,为上限定价(招股价介乎每股3.06元至4.36元),本港公开发售录超购445.57倍,经重新分配後,公开发售股数增至50%。每手800股,中签率为16%。该股将於明日(6日)上市,未来金融为独家保荐人。
公司预计集资净额为7.72亿元,当中80%主要用於在上市後五年内开发新解决方案及升级现有解决方案,方法为吸引及留住高素质技术人员、扩大公司的办公室、购买软件产品及设备以及斥资与业内专家及机构合作;10%用於加大公司的销售及营销力度;余下10%主要用作营运资金及其他一般企业用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.